Kent Wanzek - Fresenius Medical CEO
FMCQF Stock | USD 36.95 0.00 0.00% |
CEO
Mr. Kent Wanzek was Member of the Management Board, Chief Executive Officer for Global Manufacturing and Quality at Fresenius Medical Care AG Co. KGaA since January 1, 2010. From 2004 onwards, he was in charge of North American operations for the Renal Therapies Group at Fresenius Medical Care North America. Prior to joining the Company in 2003, he held several senior executive positions at Philips Medical Systems, Perkin Elmer and Baxter Healthcare Corporationrationration, among others. since 2010.
Age | 58 |
Tenure | 14 years |
Phone | 49 6172 608 2522 |
Web | https://www.freseniusmedicalcare.com |
Fresenius Medical Management Efficiency
The company has return on total asset (ROA) of 0.0253 % which means that it generated a profit of $0.0253 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0666 %, meaning that it generated $0.0666 on every $100 dollars invested by stockholders. Fresenius Medical's management efficiency ratios could be used to measure how well Fresenius Medical manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
Found 8 records | CEO Age | ||
Stephen Flatt | National HealthCare | 68 | |
Christopher Christensen | The Ensign Group | 55 | |
David Chernow | Select Medical Holdings | 67 | |
Mark Tarr | Encompass Health Corp | 62 | |
Bassam Damaj | InnovAge Holding Corp | 47 | |
April Anthony | Encompass Health Corp | 53 | |
Debra Osteen | Acadia Healthcare | 62 | |
Patrick Blair | InnovAge Holding Corp | 53 |
Management Performance
Return On Equity | 0.0666 | |||
Return On Asset | 0.0253 |
Fresenius Medical Care Leadership Team
Elected by the shareholders, the Fresenius Medical's board of directors comprises two types of representatives: Fresenius Medical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Fresenius. The board's role is to monitor Fresenius Medical's management team and ensure that shareholders' interests are well served. Fresenius Medical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Fresenius Medical's outside directors are responsible for providing unbiased perspectives on the board's policies.
Oliver Maier, Senior Vice President of Investor Relations | ||
Roberto Fuste, Member of the Management Board for Asia-Pacific | ||
Walter Weisman, Member of the Supervisory Board | ||
Michael Brosnan, CFO of Fresenius Medical Care Management AG and Member of the Management Board - Fresenius Medical Care Management AG | ||
Pascale Witz, Member of the Supervisory Board | ||
Katarzyna MazurHofsab, Management AG | ||
Borries Muller, VP Communications | ||
Kent Wanzek, Member of the Management Board - Fresenius Medical Care Management AG and CEO of Global Manufacturing and Quality - Fresenius Medical Care Management AG | ||
Joachim Weith, Sr Affairs | ||
Deborah McWhinney, Member of the Supervisory Board | ||
Robert Powell, Chairman Board | ||
Franklin FACP, Global AG | ||
Dieter Schenk, Vice Chairman of the Supervisory Board | ||
Katarzyna MazurHofsaess, Member of the Management Board | ||
Ronald Kuerbitz, Member of the Management Board - Fresenius Medical Care Management AG and CEO of Fresenius Medical Care North America - Fresenius Medical Care Management AG | ||
Dominik Wehner, Member of the Management Board for Europe, Middle East and Africa | ||
Gregor Zuend, Member of the Supervisory Board | ||
Rolf Classon, Member of the Supervisory Board | ||
Helen Giza, Chief CEO | ||
Ben Lipps, Honorary Chairman | ||
Gregor Zund, Member of the Supervisory Board | ||
Bernd Fahrholz, Member of the Supervisory Board | ||
Nwamaka MD, Head Operations | ||
William Johnston, Member of the Supervisory Board | ||
Olaf Schermeier, Member of the Management Board for Global Research & Development | ||
Dominik Heger, Head of Investor Relations & Corporate Communications | ||
Frank Maddux, Chief Medical Officer | ||
William Valle, CEO for North America, Member of the Management Board | ||
Rice Powell, Chairman of the Management Board, CEO | ||
Harry Wit, Member of the Management Board, CEO for Asia-Pacific | ||
Carla Kriwet, CEO Care | ||
Gerd Krick, Chairman of the Supervisory Board |
Fresenius Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Fresenius Medical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.0666 | |||
Return On Asset | 0.0253 | |||
Profit Margin | 0.04 % | |||
Operating Margin | 0.08 % | |||
Current Valuation | 22.64 B | |||
Shares Outstanding | 293.41 M | |||
Shares Owned By Insiders | 32.16 % | |||
Shares Owned By Institutions | 38.34 % | |||
Price To Earning | 11.60 X | |||
Price To Book | 0.58 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fresenius Medical Care. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in producer price index. You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Complementary Tools for Fresenius Pink Sheet analysis
When running Fresenius Medical's price analysis, check to measure Fresenius Medical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fresenius Medical is operating at the current time. Most of Fresenius Medical's value examination focuses on studying past and present price action to predict the probability of Fresenius Medical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fresenius Medical's price. Additionally, you may evaluate how the addition of Fresenius Medical to your portfolios can decrease your overall portfolio volatility.
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
Global Correlations Find global opportunities by holding instruments from different markets | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges |